Clinical trials: DASATINIB
Leukemia
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous…
- Trial name
- NCT00306202
- Testing
- Dasatinib
- Where
- 13 sites in Austria, France and 4 more
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days.
- Trial name
- PASS (NCT02546791)
- Testing
- Dasatinib
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
Expanded Access for Dasatinib
This is an expanded access designed to provide access to dasatinib for eligible participants.
- Trial name
- NCT00454753
- Testing
- Dasatinib
- Sponsor
- Bristol-Myers Squibb
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelomonocytic, Chronic, Leukemia-Lymphoma
Korean Post-marketing Surveillance for Sprycel®
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory…
- Trial name
- NCT01464047
- Where
- South Korea
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Pediatric
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
- Trial name
- NCT01460160
- Testing
- Dasatinib
- Where
- 128 sites in United States, Australia and 4 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute…
- Trial name
- NCT00103701
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL)…
- Trial name
- NCT00777036
- Testing
- Dasatinib
- Where
- 174 sites in United States, Argentina and 16 more
- Volunteers
- 133 people
- Sponsor
- Bristol-Myers Squibb